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concluded that: (i) FA was under no obligation to disclose the
fact that he had been treated for a sexually transmitted disease
more than 12 months before applying for membership; (ii)
information relating to the treatment of ‘acute conditions
treatable immediately’ and not related to a chronic condition, is
not material and need not be disclosed; and (iii) chronic
conditions may be regarded as material for purposes of
disclosure.
The scheme was therefore ordered to reinstate FA's
membership retrospectively.
Although it is still not clear from this case what exactly does
constitute material information for purposes of the Act, this
decision makes clear what does not. Members cannot be
penalised for not disclosing information about a condition that
was diagnosed or treated 12 months before applying for
membership and that is not present at the time of application.
In effect, this ruling means that medical schemes can no longer
require applicants to disclose full details of all medical
conditions suffered by them at any period before joining the
scheme. The Council does not appear to regard failure to
disclose a medical condition present more than 12 months
before joining the scheme, as material. Furthermore, acute
conditions present at the time of application need not be
disclosed if they are treatable immediately and do not relate to
a chronic condition.
In terms of Section 29A(2) (a) of the Act, a scheme may only
impose a 12-month condition-specific waiting period on new
members in respect of a condition for which medical advice,
diagnosis, care or treatment was recommended or received
within the 12-month period ending on the date on which an
application for membership was made. It will not assist a
scheme to argue, as Compcare did in the present case,  that it is
entitled to impose a condition-specific waiting period in
respect of a particular condition unless there is clear evidence
that the member received medical advice, diagnosis, care or
treatment for that condition within the 12-month period ending
on the date on which an application for membership was
made.
Teboho Motebele
Marlise Richter
AIDS Law Project
Centre for Applied Legal Studies
University of the Witwatersrand
Johannesburg
Endnotes
1. See for example the case of Mutual & Federal Insurance Co Ltd v Oudtshoorn Municipality 1985
(1) SA 419 (A).
2. The South African Medical Association's Human Rights and Ethical Guidelines on HIV: A
Manual for Medical Practitioners clearly states that: ‘A patient’s HIV status may only be
disclosed to a person or group if that patient consents to it being made known to that person
or group of persons....’.
3. In the case Jansen van Vuuren and Another NNO v Kruger, case no. 1993 (4) SA 733, the
Appellate Division ruled that it is vital to keep a patient's HIV status confidential.
4. The judgement is available on the AIDS Law Project website: http://www.alp.org.za.
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To the Editor: Cervical pregnancy, first described by Rubin in
1911,1 is a rare but dangerous type of ectopic pregnancy with
an incidence ranging from 1:1 000 to 1:18 000 pregnancies.2
Initially, cervical pregnancy was usually diagnosed at the time
of evacuation in the operating room with severe to
haemorrhage. Early diagnosis by ultrasound3 led to an
improvement in morbidity, but the next breakthrough was in
the early 1980s when methotrexate was introduced as a method
of treatment.3 Although internal iliac artery ligation has been
used in some cases, uterine artery embolisation came into use
during the 1990s and proved to be very effective in controlling
acute bleeding.4 In this report we describe the first case of
cervical pregnancy in an HIV-infected patient, treated by
uterine artery embolisation and methotrexate.
Case report
A 24-year-old woman, gravida 2, para 1, presented with 16
weeks’ amenorrhoea followed by lower abdominal pain and a
mild, dark vaginal bleeding of 2 days’ duration. The history
did not reveal any information of importance.
Her temperature was 36.7°C, pulse rate 54 beats/minute,
blood pressure 127/78 mmHg and respiratory rate 20/minute.
There was no detectable lymphadenopathy. The abdomen was
soft with normal bowel sounds and the uterus was not
palpable. Vaginal examination revealed a barrel-shaped cervix
with membranes visible within the external cervical os, which
was 1 cm dilated.
An ultrasound examination revealed an hourglass-shaped
uterus with the gestational sac within the cervix. A fetal pole
was visible without a heartbeat and the size of the gestational
sac was compatible with a pregnancy of 8 weeks’ duration. The
patient tested positive for HIV infection with a CD4 count of
530 x 109/l.
Primary treatment consisted of uterine embolisation via
catheterisation of the femoral arteries, with the aid of
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continuous X-ray imaging. Spongostan standard gelatin sponge
(Johnson and Johnson Medical, Skipton, UK) was cut into small
blocks (< 1 cm diameter), suspended in a saline solution with
heparin and injected into the uterine arteries with an
immediate and marked reduction in uterine blood flow.
Following the procedure, a single dose of 50 mg methotrexate
was given intramuscularly.
Three days after embolisation the patient experienced mild
suprapubic pain with a haemorrhagic vaginal discharge. An
ultrasound examination performed on the fourth day showed
an absent gestational sac with only a thickened endocervical
epithelium. On discharge from hospital the patient received
contraception in the form of depo-medroxyprogesterone
acetate 150 mg intramuscularly.
Two weeks later she presented again with acute pain just
below the umbilicus. She acknowledged having had coitus
during these 2 weeks. Her temperature was 37.5°C, pulse rate
100/minute, blood pressure 119/63 mmHg and respiratory rate
28/minute. The lower abdomen was tender on palpation
without guarding. Excitation tenderness of the cervix was
present on vaginal examination, but the cervix itself was closed
and of normal size. The adnexae were moderately tender on
both sides.
An ultrasound examination revealed a normal cervix
without other pathology in the pelvis. Analysis of her blood
gases revealed a mild respiratory alkalosis with the carbon
dioxide pressure (pCO2) 26 mmHg, oxygen pressure (pO2) 95
mmHg and pH 7.5. Her haemoglobin value was 10.6 g/dl with
a leucocytosis of 14.9 x 109/l. The human chorionic
gonadotropin (HCG) level had decreased from 39 to less than
10 mIU/l.
The patient was admitted with the clinical diagnosis of
pelvic inflammatory disease (PID) and treated with
clindamycin intravenously. The next day she improved
significantly and on the second day she was discharged from
hospital on oral clindamycin.
Discussion
There are different treatment options when a cervical
pregnancy is diagnosed. Surgical evacuation is no longer the
first line of treatment since it is impossible to remove the
trophoblast completely. Medical treatment with methotrexate is
the current first option in the management of a cervical
pregnancy, with a 94% success rate.5 An important
contraindication is acute haemorrhage which is present in
about 30% of cases.6 The remaining treatment options include
abdominal hysterectomy, endocervical tamponade and uterine
artery embolisation. Although embolisation results in acute
hypoxia of the uterus, collateral blood supplies will restore
normal blood flow within 5 - 6 weeks. Due to the hypoxia,
methotrexate should be given before embolisation if the two
methods are applied together.
Methotrexate is not the ideal first line treatment in HIV-
positive patients as it suppresses immunity in patients who are
already immune compromised. Our patient, with a normal
CD4 count of 530 x 109/l, received methotrexate before her HIV
status was known and she developed pelvic inflammatory
disease afterwards. Owing to the risk of infection,
immunosuppressants should be limited in patients with a CD4
count of more than 200 x 109/l.
Gian Urbani
Hendrik S Cronjé
Department of Obstetrics and Gynaecology
University of the Free State
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Changes in the patient population attending a primary health
care clinic in rural South Africa between 1991 and 2001
To the Editor: Serosurveys in the last decade indicate that the
prevalence of HIV infection has risen in Hlabisa district,
KwaZulu-Natal, from 4% in 1992, to 14% in 1995 and 35% in
2002.1,2 The impact of the HIV epidemic on the patient
population attending local hospitals has been reported
previously.3 In particular, there has been a marked increase in
admissions for tuberculosis and other HIV-associated
conditions. However, there are few data on the impact of the
epidemic on the burden of illness seen at primary health clinic
level. Furthermore, in 1996, primary health care became free for
all in South Africa, whereas previously patients paid a nominal
fee to see clinic staff. The impact of this change on the
attendance at primary care clinics is unknown. Such
information is needed for planning effective responses aimed
at reducing unnecessary referrals and admissions to hospital
and to enable more effective deployment of health care
workers.
To investigate possible changes in the patient population
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